Development of Potent and Selective EGFR-PROTACs Based on Macrocyclic Fourth-Generation EGFR Inhibitors
Epidermal growth factor receptor (EGFR) mutant-driven non-small cell lung cancer (NSCLC) frequently develops acquired resistance to third-generation tyrosine kinase inhibitors (TKIs), particularly through the EGFR C797S mutation. Existing EGFR-targeting proteolysis-targeting chimeras (PROTACs) remain limited by unfav...